Target intelligence / Profile preview

Protogenin (PRTG)

Target
PRTG
Molecular classification
Immunoglobulin superfamily (IgSF), DCC/neogenin subclass of IgSF, Transmembrane protein (with 4 Ig domains and 5 fibronectin type III repeats)[2], Receptor (structural and some functional evidence)[1][2]
01

Overview

Protogenin (PRTG) is a single-pass transmembrane protein belonging to the immunoglobulin superfamily, specifically the DCC/neogenin subclass. Structurally, it contains four immunoglobulin-like domains, five fibronectin type III repeats, a signal peptide, and a cytoplasmic domain. During embryogenesis, PRTG is highly expressed in neural, craniofacial, and epithelial tissues where it regulates organ patterning and suppresses premature neuronal differentiation, preserving neural progenitor states. PRTG can dimerize and acts as a cell membrane receptor; its endogenous ligand is the secreted ERdj3 protein. Knockdown or inhibition of PRTG leads to increased neurogenesis and disrupted morphogenesis in multiple tissues. Although not implicated as a therapeutic target, PRTG has been linked genetically with neurodevelopmental conditions and is essential for correct vertebral and craniofacial patterning through modulation of TGFβ signaling and HOX gene activation[1][2][3].

Other names
ProtogeninPRTGIGDCC5Protein Shen-Danimmunoglobulin superfamily DCC subclass member 5FLJ25756shen-danprotogenin homolog (Gallus gallus)
02

Mechanism of action

Not established for any drugs. Experimentally, endogenous ligand is ERdj3, a stress-inducible protein that binds to PRTG and modulates neurogenesis through PRTG signaling[1].

03

Biological functions

Regulation of early neural development; prevents premature neuronal differentiation and maintains neural progenitor pool[1]Regulation of embryonic organogenesis and epithelial morphogenesis, including roles in developing tooth germ and craniofacial structures[2]Facilitates vertebral patterning and correct HOX gene transition during axial development, partially via TGFβ signaling modulation[3]
04

Disease associations

Potential association with neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD)[1]Developmental disorders affecting neural, craniofacial, or tooth formation if PRTG function is disrupted[2][3]
05

Safety considerations

Not a current therapeutic target; no known on-target safety concerns.Knockdown or perturbation in developmental systems accelerates neuronal differentiation and disrupts normal development, indicating a critical developmental function rather than an adult therapeutic window[1][2][3].

Beyond the preview

Go deeper on Protogenin (PRTG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protogenin (PRTG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call